Warfarin and the patient who wants 'something natural' for insomnia
A 68-year-old woman attends a community herbal clinic. She has atrial fibrillation and takes warfarin, with a stable INR of 2.4 recorded two weeks ago. She also takes amlodipine for hypertension and reports no other medication. She asks for a 'natural' remedy for insomnia that has troubled her for three months, and says a friend recommended ginseng and a nightly valerian tea. She has no bleeding history, no liver disease, and does not drink alcohol. She is reluctant to 'bother the doctor' and wants to start treatment today. She also mentions she has started drinking two cups of green tea daily and has been taking a fish oil capsule for 'heart health'. She has no known allergies. Her tongue is pale with a thin white coat, and her pulse is wiry and slightly irregular.
1. Which of the patient's current substances warrant concern before any herbal prescription, and what is the pharmacological reasoning in each case?
Read the worked answer
The key concern is the combination of warfarin with agents that affect haemostasis or warfarin metabolism.
Ginseng (Panax ginseng): has been associated with reduced warfarin effect (falling INR) in some reports, plausibly through induction of hepatic metabolism. Given her stable but narrow INR, this is a real risk and should not be started without discussion with her anticoagulation service.
Fish oil: high-dose omega-3 has antiplatelet effects and may modestly increase bleeding risk when combined with warfarin. A standard capsule is probably low risk, but it should be documented and not escalated.
Green tea: contains vitamin K, and a sudden increase from none to two cups daily can lower INR. Consistency matters more than avoidance; the change should be reported so INR can be rechecked.
Valerian: evidence for a clinically important interaction with warfarin is weak, but it is sedating and has been linked to altered warfarin effect in isolated reports. It is a reasonable option only with monitoring and patient consent.
In all cases the correct action is not simply 'avoid everything' but to identify the interaction risk, inform the anticoagulation service, and arrange an INR check after any change.
2. The patient wants to start treatment today and does not want to contact her doctor. How should the practitioner proceed, and what is the professional rationale?
Read the worked answer
The practitioner should not commence a systemic herbal prescription on the day without addressing the anticoagulation risk. The professional duty is to practise within competence and to protect patient safety, which here means not introducing an agent with a plausible interaction into a patient on a narrow-therapeutic-index drug without monitoring.
A defensible plan:
Explain the specific risks in plain language, including that 'natural' does not mean interaction-free, and that an INR outside range carries stroke or bleeding risk.
Offer to write to, or ask the patient to contact, the anticoagulation clinic before starting ginseng in particular. The practitioner can provide the clinic with the proposed agents and doses.
If the patient declines all contact, the practitioner may still offer non-pharmacological support (sleep hygiene, relaxation, acupuncture if within scope and with consent) and defer the herbal prescription. This respects autonomy without colluding with an unsafe plan.
Document the discussion, the advice given, the patient's decision, and the plan to review. If the patient insists on self-medicating, provide safety-netting advice about bleeding signs and the need for INR monitoring.
Declining to prescribe is not abandonment; it is a proportionate response to an unacceptable risk that the patient has been helped to understand.
3. If a monitored trial of valerian were later agreed, what dose, duration and review points would you specify, and what would you tell the patient to watch for?
Read the worked answer
A cautious trial would use a standardised valerian root preparation at a conventional label dose (for example the equivalent of 300–600 mg of dry root extract taken 30–60 minutes before bed), for a defined period such as two to four weeks, with review before any continuation.
Before starting, the anticoagulation service should be informed so that an INR check can be scheduled roughly one to two weeks after initiation, and again after any dose change. The patient should keep green tea intake constant rather than stopping or increasing it, and should not add other sedatives, including alcohol or over-the-counter sleep aids, without checking.
Safety-netting advice: report unusual bruising, nosebleeds that take more than ten minutes to stop, blood in urine or stool, black stools, unusual headache, or any fall or head injury. Report excessive daytime drowsiness, and do not drive if sedated. Stop the valerian and seek advice if any of these occur.
Review should assess sleep, daytime function, bleeding symptoms, and the INR result. If there is no meaningful benefit by four weeks, stop rather than continue indefinitely. All of this should be documented and shared with the patient in writing where possible.